ABSTRACT
Chromosomal rearrangements with duplication of the lamin B1 (LMNB1) gene underlie autosomal dominant adult-onset demyelinating leukodystrophy (ADLD), a rare neurological disorder in which overexpression of LMNB1 causes progressive central nervous system demyelination. However, we previously reported an ADLD family (ADLD-1-TO) without evidence of duplication or other mutation in LMNB1 despite linkage to the LMNB1 locus and lamin B1 overexpression. By custom array-CGH, we further investigated this family and report here that patients carry a large (â¼660 kb) heterozygous deletion that begins 66 kb upstream of the LMNB1 promoter. Lamin B1 overexpression was confirmed in further ADLD-1-TO tissues and in a postmortem brain sample, where lamin B1 was increased in the frontal lobe. Through parallel studies, we investigated both loss of genetic material and chromosomal rearrangement as possible causes of LMNB1 overexpression, and found that ADLD-1-TO plausibly results from an enhancer adoption mechanism. The deletion eliminates a genome topological domain boundary, allowing normally forbidden interactions between at least three forebrain-directed enhancers and the LMNB1 promoter, in line with the observed mainly cerebral localization of lamin B1 overexpression and myelin degeneration. This second route to LMNB1 overexpression and ADLD is a new example of the relevance of regulatory landscape modifications in determining Mendelian phenotypes.
Subject(s)
Enhancer Elements, Genetic , Lamin Type B/genetics , Pelizaeus-Merzbacher Disease/genetics , Sequence Deletion , Animals , Base Sequence , Cells, Cultured , DNA Mutational Analysis , Female , Gene Expression , Gene Expression Regulation , Genetic Association Studies , Humans , Lamin Type B/metabolism , Male , Mice, Transgenic , Middle Aged , Molecular Sequence Data , PedigreeABSTRACT
OBJECTIVES: Tumour necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) is a multisystemic autoinflammatory condition associated with heterozygous TNFRSF1A mutations, presenting with a variety of clinical symptoms, many of which yet unexplained. In this work, we aimed at deepening into TRAPS pathogenic mechanisms sustained by monocytes. METHODS: Microarray experiments were conducted to identify genes whose expression results altered in patients compared to healthy individuals, both under basal condition and following LPS stimulation. RESULTS: An inflammatory state baseline, characterised by constitutive overexpression of IL1ß and IL1R1 receptor, has been shown in TRAPS patients compared to controls, including in non-active disease phases. Following LPS stimulation, IL1RN up-regulation is stronger in controls than in patients and inflammatory pathways and microRNAs undergo differential regulation. Genes involved in post-translational modifications, protein folding and ubiquitination result constitutively up-regulated in TRAPS, while response to interferon types I and II is defective, failing to be up-regulated by LPS. TGFß pathway is down-regulated in untreated TRAPS monocytes, while genes involved in redox regulation result constitutively over-expressed. Finally, additional molecular alterations seem to reflect organ failures sometime complicating the disease. CONCLUSIONS: Gene expression profile in resting TRAPS monocytes has confirmed the patients' chronic inflammatory condition. In addition, pathways not yet associated with the disease have been disclosed, such as interferon types I and II response to LPS stimulation and a downregulation of the TGFß pathway in basal condition. The role of miRNA, suggested by our results, deserves in-depth analyses in light of the possible development of targeted therapies.
Subject(s)
Fever/genetics , Gene Expression Regulation , Hereditary Autoinflammatory Diseases/genetics , Inflammation Mediators/metabolism , Monocytes/metabolism , Adolescent , Case-Control Studies , Child , Child, Preschool , Female , Fever/diagnosis , Fever/immunology , Fever/metabolism , Gene Expression Profiling/methods , Gene Expression Regulation/drug effects , Genetic Association Studies , Genetic Markers , Genetic Predisposition to Disease , Hereditary Autoinflammatory Diseases/diagnosis , Hereditary Autoinflammatory Diseases/immunology , Hereditary Autoinflammatory Diseases/metabolism , Heterozygote , Humans , Inflammation Mediators/immunology , Interleukin 1 Receptor Antagonist Protein/genetics , Interleukin 1 Receptor Antagonist Protein/metabolism , Lipopolysaccharides/pharmacology , Male , Monocytes/drug effects , Monocytes/immunology , Mutation , Oligonucleotide Array Sequence Analysis , Phenotype , Polymerase Chain Reaction , Receptors, Tumor Necrosis Factor, Type I/genetics , Receptors, Tumor Necrosis Factor, Type I/immunology , Reproducibility of ResultsABSTRACT
The architecture and structural mechanics of the cell nucleus are defined by the nuclear lamina, which is formed by A- and B-type lamins. Recently, gene duplication and protein overexpression of lamin B1 (LB1) have been reported in pedigrees with autosomal dominant leukodystrophy (ADLD). However, how the overexpression of LB1 affects nuclear mechanics and function and how it may result in pathology remain unexplored. Here, we report that in primary human skin fibroblasts derived from ADLD patients, LB1, but not other lamins, is overexpressed at the nuclear lamina and specifically enhances nuclear stiffness. Transient transfection of LB1 in HEK293 and neuronal N2a cells mimics the mechanical phenotype of ADLD nuclei. Notably, in ADLD fibroblasts, reducing LB1 protein levels by shRNA knockdown restores elasticity values to those indistinguishable from control fibroblasts. Moreover, isolated nuclei from ADLD fibroblasts display a reduced nuclear ion channel open probability on voltage-step application, suggesting that biophysical changes induced by LB1 overexpression may alter nuclear signaling cascades in somatic cells. Overall, the overexpression of LB1 in ADLD cells alters nuclear mechanics and is linked to changes in nuclear signaling, which could help explain the pathogenesis of this disease.
Subject(s)
Cell Nucleus/pathology , Embryo, Mammalian/cytology , Fibroblasts/pathology , Lamin Type B/metabolism , Pelizaeus-Merzbacher Disease/pathology , Skin/cytology , Adult , Animals , Blotting, Western , Case-Control Studies , Cell Membrane Permeability , Cell Nucleus/genetics , Cell Nucleus/metabolism , Cell Proliferation , Cells, Cultured , Embryo, Mammalian/metabolism , Female , Fibroblasts/metabolism , Flow Cytometry , Fluorescent Antibody Technique , Humans , Lamin Type B/antagonists & inhibitors , Lamin Type B/genetics , Male , Mice , Middle Aged , Patch-Clamp Techniques , Pelizaeus-Merzbacher Disease/genetics , Pelizaeus-Merzbacher Disease/metabolism , Phenotype , RNA, Small Interfering/genetics , Skin/metabolismABSTRACT
Regulated expression of positive and negative regulatory factors controls the extent and duration of T cell adaptive immune response preserving the organism's integrity. Calreticulin (CRT) is a major Ca2+ buffering chaperone in the lumen of the endoplasmic reticulum. Here we investigated the impact of CRT deficiency on T cell function in immunodeficient mice reconstituted with fetal liver crt-/- hemopoietic progenitors. These chimeric mice displayed severe immunopathological traits, which correlated with a lower threshold of T cell receptor (TCR) activation and exaggerated peripheral T cell response to antigen with enhanced secretion of inflammatory cytokines. In crt-/- T cells TCR stimulation induced pulsatile cytosolic elevations of Ca2+ concentration and protracted accumulation of nuclear factor of activated T cells in the nucleus as well as sustained activation of the mitogen-activated protein kinase pathways. These observations support the hypothesis that CRT-dependent shaping of Ca2+ signaling critically contributes to the modulation of the T cell adaptive immune response.
Subject(s)
Calreticulin/physiology , Lymphocyte Activation , T-Lymphocytes/immunology , T-Lymphocytes/metabolism , Animals , Calreticulin/deficiency , Calreticulin/genetics , Cell Differentiation/genetics , Cell Differentiation/immunology , Cells, Cultured , Clonal Anergy/genetics , Clonal Anergy/immunology , Female , Immunologic Memory/genetics , Liver/immunology , Liver/pathology , Lymphocyte Activation/genetics , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Knockout , Mice, Transgenic , Radiation Chimera/immunology , Signal Transduction/genetics , Signal Transduction/immunology , T-Lymphocytes, Regulatory/immunology , Thymus Gland/immunology , Thymus Gland/metabolism , Thymus Gland/pathologyABSTRACT
OBJECTIVE: To evaluate the rate of somatic NLRP3 mosaicism in an Italian cohort of mutation-negative patients with cryopyrin-associated periodic syndrome (CAPS). METHODS: The study enrolled 14 patients with a clinical phenotype consistent with CAPS in whom Sanger sequencing of the NLRP3 gene yielded negative results. Patients' DNA were subjected to amplicon-based NLRP3 deep sequencing. RESULTS: Low-level somatic NLRP3 mosaicism has been detected in 4 patients, 3 affected with chronic infantile neurological cutaneous and articular syndrome and 1 with Muckle-Wells syndrome. Identified nucleotide substitutions encode for 4 different amino acid exchanges, with 2 of them being novel (p.Y563C and p.G564S). In vitro functional studies confirmed the deleterious behavior of the 4 somatic NLRP3 mutations. Among the different neurological manifestations detected, 1 patient displayed mild loss of white matter volume on brain magnetic resonance imaging. CONCLUSION: The allele frequency of somatic NLRP3 mutations occurs generally under 15%, considered the threshold of detectability using the Sanger method of DNA sequencing. Consequently, routine genetic diagnostic of CAPS should be currently performed by next-generation techniques ensuring high coverage to identify also low-level mosaicism, whose actual frequency is yet unknown and probably underestimated.
Subject(s)
Brain/diagnostic imaging , Cryopyrin-Associated Periodic Syndromes/genetics , Mosaicism , NLR Family, Pyrin Domain-Containing 3 Protein/genetics , Child , Child, Preschool , Cryopyrin-Associated Periodic Syndromes/diagnostic imaging , Female , High-Throughput Nucleotide Sequencing , Humans , Infant , Infant, Newborn , Italy , Magnetic Resonance Imaging , Male , White Matter/diagnostic imagingABSTRACT
In Alzheimer's disease (AD), amyloid-ß (Aß) deposits accumulate in the brain parenchyma and contain fibrils of aggregated heterogeneous Aß peptides. In addition to fibrils, Aß aggregates into stable soluble species (termed Aß oligomers), which are increasingly viewed as the key drivers of early neurodegenerative events in AD. Aß aggregates stimulate microglia recruitment and activation. In the AD brain, microglia surround Aß deposits, activate, and abnormally produce inflammatory mediators, contributing to AD pathogenesis. However, it remains unclear to which of the conformationally diverse Aß species microglia specifically react. Here, we explore the "sensor" capability of murine microglia. We examine whether they can detect and discriminate the toxic Aß oligomers, Aß fibrils, and Aß-induced neuronal damage and investigate whether they are activated by diverse human Aß species cell autonomously or through neuron-derived factors. We find that, on aggregation in vitro, Aß42 peptides form stable oligomers and fibrils, which are neurotoxic and trigger dendritic spine loss in mature primary mouse hippocampal neurons. Further, in resting primary murine microglia, Aß42 fibrils induce a pattern of expression of inflammatory genes typical of the classical inflammatory response induced by infectious agents (e.g., the bacterial toxin lipopolysaccharide). Conversely, Aß42 oligomers never elicit a microglia inflammatory response, whether applied alone, in combination with neuron-derived secreted factors, or in contact with neurons. Thus, microglia strongly react to Aß42 fibrils, but do not sense Aß oligomers or oligomer-induced neuronal damage. This suggests that early neurotoxic species can escape detection by microglia, leading to the chronic unfolding of amyloid pathology in AD.
Subject(s)
Alzheimer Disease/etiology , Amyloid beta-Peptides/metabolism , Amyloid/metabolism , Microglia/metabolism , Microglia/physiology , Peptide Fragments/metabolism , Protein Aggregates , Protein Aggregation, Pathological/etiology , Protein Aggregation, Pathological/metabolism , Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Animals , Brain/metabolism , CHO Cells , Cells, Cultured , Cricetinae , Cricetulus , Female , Inflammation Mediators/metabolism , Male , Mice, Inbred C57BL , PregnancyABSTRACT
The pre-T cell receptor (pre-TCR) promotes the development of thymocytes with productive rearrangement at the TCR beta chain locus by signaling in a ligand-independent fashion. The TCR beta chain associates with the invariant pre-Talpha (pTalpha) chain, which bears specific charged residues in the extracellular portion mediating pre-TCR self-oligomerization. In recombinase-deficient thymocytes, calnexin (CNX) associated with CD3 chains is inefficiently retained in the endoplasmic reticulum (ER) and weakly expressed in the plasma membrane. Deliberate cross-linking of CNX/CD3 complexes mimics pre-TCR signaling. Here, we show that, analogously to the pTalpha chain, surface CNX is palmitoylated and that CD3 prominently accumulated in lipid rafts upon cross-linking. Mutant CNX isoforms devoid of ER retention determined pre-TCR-like signaling and simulated beta selection only when stably translocating CD3 to lipid rafts. Inclusion of the palmitoylated cytoplasmic tail from the pTalpha chain in recombinant CNX strikingly improved the pre-TCR-like signaling efficiency of CNX/CD3 in rafts. This study indicates that lipid rafts in the plasma membrane represent proficient microdomains for the initiation of pre-TCR signaling, and supports the view that beta selection by oligomerized pre-TCR is implemented by the pTalpha cytoplasmic tail.
Subject(s)
CD3 Complex/metabolism , Cell Differentiation , Membrane Microdomains/metabolism , Recombinases/deficiency , T-Lymphocytes/cytology , T-Lymphocytes/immunology , Animals , CD3 Complex/immunology , Calnexin/genetics , Calnexin/metabolism , Cell Differentiation/immunology , Cells, Cultured , Lipoylation , Membrane Microdomains/immunology , Membrane Proteins/metabolism , Mice , Mutation/genetics , Protein Binding , Recombinases/genetics , Recombinases/metabolism , T-Lymphocytes/metabolismABSTRACT
HMGB1, a non-histone nuclear factor, acts extracellularly as a mediator of delayed endotoxin lethality, which raises the question of how a nuclear protein can reach the extracellular space. We show that activation of monocytes results in the redistribution of HMGB1 from the nucleus to cytoplasmic organelles, which display ultrastructural features of endolysosomes. HMGB1 secretion is induced by stimuli triggering lysosome exocytosis. The early mediator of inflammation interleukin (IL)-1beta is also secreted by monocytes through a non-classical pathway involving exocytosis of secretory lysosomes. However, in keeping with their respective role of early and late inflammatory factors, IL-1beta and HMGB1 respond at different times to different stimuli: IL-1beta secretion is induced earlier by ATP, autocrinally released by monocytes soon after activation; HMGB1 secretion is triggered by lysophosphatidylcholine, generated later in the inflammation site. Thus, in monocytes, non-classical secretion can occur through vescicle compartments that are at least partially distinct.
Subject(s)
Cell Nucleus/metabolism , HMGB1 Protein/metabolism , Monocytes/metabolism , Blotting, Western , Cell Nucleus/ultrastructure , Cytoplasm/metabolism , Fluorescent Antibody Technique , Humans , Immunohistochemistry , Inflammation , Kinetics , L-Lactate Dehydrogenase/metabolism , Lipopolysaccharides/chemistry , Lysophosphatidylcholines/metabolism , Microscopy, Fluorescence , Microscopy, Immunoelectron , Subcellular Fractions , Time Factors , beta-N-Acetylhexosaminidases/metabolismABSTRACT
High Mobility Group 1 protein (HMGB1) is a chromatin component that, when leaked out by necrotic cells, triggers inflammation. HMGB1 can also be secreted by activated monocytes and macrophages, and functions as a late mediator of inflammation. Secretion of a nuclear protein requires a tightly controlled relocation program. We show here that in all cells HMGB1 shuttles actively between the nucleus and cytoplasm. Monocytes and macrophages acetylate HMGB1 extensively upon activation with lipopolysaccharide; moreover, forced hyperacetylation of HMGB1 in resting macrophages causes its relocalization to the cytosol. Cytosolic HMGB1 is then concentrated by default into secretory lysosomes, and secreted when monocytic cells receive an appropriate second signal.